Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.41 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.39 |
| ▸ | CCR9 | P51686 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29632032 | 0.90 | NR1H2 (0.44) | NR1H2USP30NR1H3OXER1CCNB2 | |
| SCHEMBL27112011 | 0.88 | USP30 (0.42) | NR1H2USP30NR1H3OXER1CCR9 | |
| SCHEMBL25337853 | 0.87 | NR1H2 (0.44) | NR1H2USP30NR1H3OXER1CCR9 | |
| SCHEMBL19013558 | 0.85 | NR1H2 (0.43) | NR1H2NR1H3CCR9 | |
| SCHEMBL5058104 | 0.84 | NR1H2 (0.41) | NR1H2NR1H3 | |
| SCHEMBL29631929 | 0.84 | NR1H2 (0.41) | NR1H2NR1H3OXER1CCR9 | |
| SCHEMBL18989952 | 0.84 | NR1H2 (0.41) | NR1H2NR1H3OXER1CCR9 | |
| SCHEMBL26684287 | 0.84 | NR1H2 (0.47) | NR1H2USP30NR1H3OXER1CCR9 | |
| SCHEMBL26683840 | 0.83 | L3MBTL1 (0.44) | NR1H2USP30NR1H3OXER1CCR9 | |
| SCHEMBL30041137 | 0.83 | NR1H2 (0.46) | NR1H2NR1H3OXER1CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| EP-4680247-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | Insmed Incorporated (US) | 2026-01-21 | — | — | EP | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| CN-117242067-B | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| WO-2024192416-A1 | DPP1 INHIBITORS WITH POLYCYCLIC LINKERS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-09-19 | — | — | WO | disclosed |
| EP-4353717-A1 | NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST | Mindrank AI Ltd. (CN) | 2024-04-17 | — | — | EP | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2024-02-29 | — | — | US | disclosed |
| CN-117242067-A | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023029380-A1 | NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST | 杭州德睿智药科技有限公司 | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | GLP1R, GIPR, GCGR | NR1H2 682/4885USP30 3579/4885NR1H3 967/4885 |
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | GLP1R, GIPR, GCGR | NR1H2 194/4885USP30 1751/4885NR1H3 409/4885 |
| US-20240067630-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | NR1H2 571/4885USP30 3568/4885NR1H3 924/4885 |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | NR1H2 267/4885USP30 2770/4885NR1H3 525/4885 |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | GLP1R, GIPR, GCGR | NR1H2 633/4885USP30 3534/4885NR1H3 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.